Government biomarker regulation

Introduction

Government biomarker regulation concerns the legal framework governing the collection, analysis, validation, storage, sharing, and use of biological indicators that provide information about a person's physiological, genetic, biochemical, or disease-related characteristics. Biomarkers may include genetic variants, blood-based indicators, hormone levels, antibodies, proteins, metabolic indicators, and other measurable biological characteristics. Governments regulate biomarkers because their use can influence healthcare, public health surveillance, pharmaceutical research, employment, insurance, criminal investigations, and access to public services.

Biomarker regulation combines principles of health law, biotechnology law, data protection, medical-device regulation, bioethics, constitutional rights, and administrative law. The central regulatory challenge is to encourage beneficial medical innovation while preventing misuse of highly sensitive biological information.

Regulatory classification of biomarkers

A government may regulate a biomarker differently depending upon its intended purpose. A biomarker used solely for scientific research may face fewer regulatory requirements than a biomarker used to diagnose disease or determine treatment.

Diagnostic biomarkers are commonly regulated through laws governing medical devices, laboratory-developed tests, in-vitro diagnostic products, or medicines. Where a biomarker is used to predict whether a patient will respond to a particular medicine, additional requirements concerning clinical validity and analytical validity may apply.

The distinction between analytical validity, clinical validity, and clinical utility is particularly important. Analytical validity asks whether a test accurately measures the biomarker. Clinical validity concerns whether the biomarker accurately predicts or identifies a clinical condition. Clinical utility asks whether using the biomarker actually improves healthcare outcomes.

Government regulators therefore have to establish evidence standards before allowing biomarkers to be incorporated into clinical decision-making.

Privacy and protection of biomarker information

Biomarker information can reveal extremely sensitive characteristics. Genetic biomarkers may additionally provide information concerning biological relatives. Consequently, governments increasingly treat genetic and health information as specially protected categories of personal data.

The European Union's General Data Protection Regulation (GDPR) provides enhanced protection for genetic and health data. Processing such information generally requires a lawful basis and compliance with principles such as purpose limitation, data minimisation, transparency, security, and accountability.

The Court of Justice of the European Union in Digital Rights Ireland Ltd v. Ireland (Joined Cases C-293/12 and C-594/12) emphasised that large-scale retention of sensitive information can seriously interfere with privacy and data-protection rights. Although the case concerned telecommunications data rather than biomarkers, its reasoning is relevant to governmental retention and processing of sensitive biological information.

Genetic biomarkers and discrimination

Genetic biomarkers create particular concerns because information obtained for medical purposes can potentially be used for employment, insurance, or other decisions.

The United States enacted the Genetic Information Nondiscrimination Act 2008 (GINA), restricting certain uses of genetic information by employers and health insurers.

The U.S. Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013) is also significant to biomarker governance. The Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated, while synthetically created complementary DNA could receive different treatment. The judgment demonstrates the legal distinction between naturally occurring biological information and human-created biotechnology.

This distinction is important because government regulation must determine what aspects of biomarker technology can legitimately be controlled through intellectual-property and regulatory frameworks.

Biomarker testing and medical regulation

Where biomarker testing is used for diagnosis or treatment, governments generally require reliable testing methodologies. Regulators may require laboratories and manufacturers to demonstrate accuracy, reliability, reproducibility, and clinical effectiveness.

The regulatory framework may include licensing of laboratories, quality-control requirements, proficiency testing, reporting standards, informed-consent requirements, and post-market surveillance.

The legal objective is to prevent unreliable biomarker tests from producing incorrect diagnoses or inappropriate treatment decisions.

The United States Food and Drug Administration (FDA) has developed regulatory approaches for in-vitro diagnostic products and companion diagnostics. Companion diagnostics can identify patients who are likely to benefit from a particular therapeutic product, making regulatory coordination between diagnostic and pharmaceutical authorities especially important.

Biomarkers in pharmaceutical development

Biomarkers are increasingly used in clinical trials to identify patient populations, measure treatment response, and predict adverse reactions. Governments therefore regulate their use in pharmaceutical research.

A biomarker may become a surrogate endpoint, allowing researchers or regulators to assess a biological effect as an indicator of a potential clinical benefit. However, reliance on surrogate endpoints can create legal and scientific concerns if a biological change does not ultimately translate into improved patient outcomes.

Regulatory authorities consequently require appropriate scientific evidence before accepting biomarkers as reliable indicators for drug approval or post-approval obligations.

Informed consent and bodily autonomy

Biomarker regulation also involves the legal rights of individuals whose biological samples are collected.

Obtaining blood, tissue, saliva, or other biological material can raise questions concerning informed consent, autonomy, privacy, secondary research use, and withdrawal of consent.

In Montgomery v. Lanarkshire Health Board [2015] UKSC 11, the UK Supreme Court strengthened the importance of patient autonomy and adequate disclosure of material medical risks. Although the case did not specifically concern biomarkers, its principles concerning informed medical decision-making are relevant to biomarker testing where results may significantly affect a person's healthcare choices.

In India, constitutional privacy principles are particularly important. In Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) 10 SCC 1, the Supreme Court recognised privacy as a fundamental right under Article 21 of the Constitution. The judgment provides a significant constitutional foundation for protecting sensitive biological and genetic information.

Government biomarker databases

Governments may establish biomarker databases for public-health research, disease surveillance, genomic medicine, or forensic purposes. Such databases create substantial benefits but also raise questions concerning retention, access, cybersecurity, secondary use, and governmental oversight.

A legitimate database should ordinarily specify:

• the purpose for collecting biomarker information;
• categories of individuals whose information may be collected;
• retention periods;
• authorised users;
• security safeguards;
• conditions for data sharing;
• procedures for correction or deletion where legally applicable; and
• independent oversight.

Government access should be proportionate to the legitimate objective. Unlimited or indefinite collection creates risks of function creep, where information collected for one purpose is later used for unrelated governmental purposes.

Biomarkers in public-health emergencies

During epidemics and pandemics, biomarkers can assist with diagnosis, immunity assessment, disease surveillance, and population-level research. Emergency conditions may justify accelerated regulatory procedures, but they do not eliminate the need for scientific validation and legal safeguards.

Governments may introduce emergency authorisations for diagnostic tests when conventional approval procedures would take too long. Such measures should remain subject to evidence requirements, monitoring, adverse-event reporting, and mechanisms for withdrawal when evidence proves inadequate.

The COVID-19 experience demonstrated the importance of distinguishing between emergency access and permanent regulatory approval.

Biomarker regulation and equality

Biomarker-based healthcare can create inequalities if advanced testing is available only to wealthy populations. Government regulation may therefore include reimbursement requirements, public-health programmes, subsidised testing, or universal-access initiatives.

Equality concerns also arise when biomarker algorithms perform differently across demographic populations because the underlying research datasets are not sufficiently representative.

Government agencies should therefore require evidence concerning population diversity, test performance, and potential discriminatory effects before biomarkers are incorporated into important public decisions.

Administrative accountability

Government biomarker regulators exercise significant technical and administrative powers. Their decisions should therefore be based on evidence and remain subject to appropriate administrative review.

Regulators should publish scientific standards, explain significant decisions, maintain conflict-of-interest safeguards, and establish appeal mechanisms. Independent scientific committees can assist in evaluating biomarker evidence, particularly where the technology is novel.

Judicial review can provide an additional safeguard against arbitrary or unlawful regulatory action. Courts generally avoid substituting their scientific judgment for that of specialist regulators but can examine whether the regulator acted within its statutory authority and followed lawful procedures.

Conclusion

Government biomarker regulation is an emerging area connecting biomedical science, public health, privacy, constitutional law, medical regulation, biotechnology, and administrative governance. Effective regulation must ensure that biomarkers are scientifically reliable while protecting individuals from privacy violations, discrimination, unauthorised biological-data use, and unsafe medical decision-making.

Important jurisprudence includes Justice K.S. Puttaswamy v. Union of India, establishing constitutional privacy protections in India; Association for Molecular Pathology v. Myriad Genetics, addressing legal treatment of naturally occurring genetic material; Digital Rights Ireland, demonstrating the importance of proportionality in large-scale sensitive-data retention; and Montgomery v. Lanarkshire Health Board, reinforcing patient autonomy in medical decision-making.

The emerging regulatory principle is therefore that biomarker innovation should be permitted where supported by reliable evidence, but its collection and use must remain lawful, necessary, proportionate, scientifically validated, privacy-protective, and accountable to independent oversight.